Gilead and No­vo Nordisk ex­pand NASH deal with new study; Pfiz­er out-li­cens­es AD­Cs to a biotech start­up

Pfiz­er has out-li­censed a pair of an­ti­body-drug con­ju­gates to Cam­bridge, MA-based Pyx­is On­col­o­gy.

Pyx­is is hand­ing over an un­spec­i­fied up­front pay­ment, mile­stones and a chunk of eq­ui­ty to Pfiz­er, and al­so gains rights to Pfiz­er’s ADC plat­form, “in­clud­ing var­i­ous pay­load class­es, link­er tech­nol­o­gy and site-spe­cif­ic con­ju­ga­tion tech­niques for the fu­ture de­vel­op­ment of ad­di­tion­al AD­Cs.”

Ronald Herb­st, the CSO at Long­wood-fund­ed Pyx­is, said:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.